Literature DB >> 2055197

The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84).

L Mosekilde1, C H Søgaard, C C Danielsen, O Tørring.   

Abstract

PTH has a proven anabolic effect on bone mass, as has been shown in several animal models and treatment regimens. The aim of this study was to ascertain whether the positive effect on bone mass is also reflected in the quality of bone formed. The study was performed in a rat model using human PTH (hPTH). One hundred and twenty male Wistar rats, divided into 10 groups, were given either hPTH-(1-34) or hPTH-(1-84) in daily sc doses. Dose levels ranged from 0.11-3.00 nmol/100 g BW.day for a period of 30 days. At death all six lumbar vertebrae were obtained from each rat. A combination of methods was applied to these vertebral bodies in order to ascertain the effect of hPTH on vertebral bone volume, density, trabecular structure, and biomechanical competence. The results revealed a dose-dependent increase in total volume, dry weight, ash weight, and trabecular bone volume. Also, a dose-dependent increase in load values could be demonstrated. The increase in bone strength remained significant after normalization for both cross-sectional area and bone mass. This indicates that the increase in bone size and bone mass was not achieved at the expense of the quality of the bone present. When the two treatments were administered at the same molar dose level, no difference between hPTH-(1-34) and hPTH-(1-84) was revealed. On the basis of this study, it is concluded that PTH could prove to be a promising treatment in the management of osteopenic states.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2055197     DOI: 10.1210/endo-129-1-421

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

Review 1.  Parathyroid hormone analogues in the treatment of osteoporosis.

Authors:  Marius E Kraenzlin; Christian Meier
Journal:  Nat Rev Endocrinol       Date:  2011-07-12       Impact factor: 43.330

2.  Discovery of a Positive Allosteric Modulator of the Thyrotropin Receptor: Potentiation of Thyrotropin-Mediated Preosteoblast Differentiation In Vitro.

Authors:  Susanne Neumann; Elena Eliseeva; Alisa Boutin; Elena Barnaeva; Marc Ferrer; Noel Southall; David Kim; Xin Hu; Sarah J Morgan; Juan J Marugan; Marvin C Gershengorn
Journal:  J Pharmacol Exp Ther       Date:  2017-10-31       Impact factor: 4.030

Review 3.  Parathyroid hormone as an anabolic skeletal therapy.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.

Authors:  J Y Reginster; A N Taquet; G Fraikin; C Gosset; B Zegels
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

5.  Restoration of severely depleted femoral trabecular bone in ovariectomized rats by parathyroid hormone-(1-34).

Authors:  J F Whitfield; P Morley; V Ross; R J Isaacs; R H Rixon
Journal:  Calcif Tissue Int       Date:  1995-03       Impact factor: 4.333

6.  Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol.

Authors:  M Neer; D M Slovik; M Daly; T Potts; S R Nussbaum
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

7.  Oxidation of recombinant human parathyroid hormone: effect of oxidized position on the biological activity.

Authors:  Y Nabuchi; E Fujiwara; K Ueno; H Kuboniwa; Y Asoh; H Ushio
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

8.  The stability and degradation pathway of recombinant human parathyroid hormone: deamidation of asparaginyl residue and peptide bond cleavage at aspartyl and asparaginyl residues.

Authors:  Y Nabuchi; E Fujiwara; H Kuboniwa; Y Asoh; H Ushio
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

9.  Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women.

Authors:  Esteban Jódar-Gimeno
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

10.  Denosumab: an investigational drug for the management of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.